DesignLong-term preclinical normal-aging intervention study in chow-fed wild-type C57BL/6N mice
PopulationNormally aging C57BL/6N mice
SampleMultiple long-term mouse cohorts; see publication
InterventionLong-term oral NMN administration for up to 12 months
EndpointsTissue NAD+; Body weight; Energy metabolism; Physical activity; Insulin sensitivity; Plasma lipid profile; Eye function; Mitochondrial metabolism; Age-related gene expression
What the publication reported
This landmark study administered NMN long term to normally aging mice and measured a broad range of physiological and molecular outcomes over roughly one year.
NMN was used to synthesize tissue NAD+ and was associated with less age-related weight gain, altered energy metabolism and activity, improved insulin sensitivity and lipid measures, and changes in eye function, mitochondrial metabolism and age-associated gene expression.
Because this was a mouse study, its broad aging-related findings are mechanistic and hypothesis-generating. They do not establish that NMN slows human aging or extends human healthspan or lifespan.
Key findings
Oral NMN increased tissue NAD+ availability in mice.
Long-term treatment mitigated several age-associated physiological changes in the studied mice.
Energy metabolism, physical activity, insulin sensitivity and lipid measures were among the reported outcomes.
The study reported no obvious toxicity under its experimental conditions.
Gene-expression and mitochondrial changes accompanied the physiological findings.
What it cannot establish
Mouse study, not a human trial.
Broad phenotyping creates many possible outcome comparisons.
Mouse lifespan, metabolism and dosing differ substantially from humans.
The study did not establish human lifespan or healthspan effects.
Commercial-affiliation context should be considered when interpreting translational claims.
HealthspanX claim boundary: This study does not establish that NMN slows human aging, extends human lifespan, or improves human healthspan.
